EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Enhancing CAR T cells function: role of immunomodulators in cancer immunotherapy

Maheen Rehman, Ariba Qaiser, Hassan Sardar Khan, Sobia Manzoor, Javed Ashraf

Clinical and Experimental Medicine · 2024

DOI: 10.1007/s10238-024-01442-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Experimental Medicine, 2024. Verfasst von Maheen Rehman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Virology Lab, Atta-Ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Eastern Finland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CAR T-cell therapy is a promising immunotherapy, providing successful results for cancer patients who are unresponsive to standard and traditional therapeutic approaches. However, there are limiting factors which create a hurdle in the therapy performing its role optimally. CAR T cells get exhausted, produce active antitumor responses, and might even produce toxic reactions. Specifically, in the case of solid tumors, chimeric antigen receptor T (CAR-T) cells fail to produce the desired outcomes. Then, the need to use supplementary agents such as immune system modifying immunomodulatory agents comes into play. A series of the literature was studied to evaluate the role of immunomodulators including a phytochemical, Food and Drug Administration (FDA)-approved targeted drugs, and ILs in support of their achievements in boosting the efficiency of CAR-T cell therapy. Some of the most promising out of them are reported in this article. It is expected that by using the right combinations of immunotherapy, immunomodulators, and traditional cancer treatments, the best possible cancer defying results may be produced in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansImmunologic FactorsImmunomodulating AgentsT-LymphocytesImmunotherapy

Stichwörter der Autor:innen

CAR T cellsCancerCombinatory therapyImmunomodulatorsImmunotherapy

Substanzen

Receptors, Chimeric AntigenImmunologic FactorsImmunomodulating Agents

Autor:innen und Institutionen

  • Molecular Virology Lab, Atta-Ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan.
  • Institute of Dentistry, University of Eastern Finland, Kuopio, Finland. Javeda@student.uef.fi.
  • Riphah International University, Islamabad, Pakistan. Javeda@student.uef.fi.

Förderung

  • University of Eastern Finland

Zitieren

APA

Rehman, M., Qaiser, A., Khan, H. S., Manzoor, S., & Ashraf, J. (2024). Enhancing CAR T cells function: role of immunomodulators in cancer immunotherapy. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-024-01442-9

Vancouver

Rehman M, Qaiser A, Khan HS, Manzoor S, Ashraf J. Enhancing CAR T cells function: role of immunomodulators in cancer immunotherapy. Clinical and Experimental Medicine. 2024. doi:10.1007/s10238-024-01442-9

BibTeX
@article{Rehman2024,
  author = {Rehman, Maheen and Qaiser, Ariba and Khan, Hassan Sardar and Manzoor, Sobia and Ashraf, Javed},
  title = {Enhancing CAR T cells function: role of immunomodulators in cancer immunotherapy},
  journal = {Clinical and Experimental Medicine},
  year = {2024},
  doi = {10.1007/s10238-024-01442-9}
}
Kostenlos starten →